Organogenesis Holdings (ORGO) Other Non-Current Assets (2017 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Other Non-Current Assets of $16.1 million for Q1 2026, up 176.47% year-over-year from $5.8 million in Q1 2025, and up 75.26% quarter-over-quarter from $9.2 million in Q4 2025.
Organogenesis Holdings (ORGO) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $16.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 176.47% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 176.47% YoY), while the FY2025 annual figure was $9.2 million, up 83.88% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $16.1 million, up from $9.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $16.1 million in Q1 2026, with the low at $1.3 million in Q3 2023.
- The 5-year median for Other Non-Current Assets is $5.0 million (2024), against an average of $5.5 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets slipped 16.87% in 2023, then surged 358.58% in 2024.
- Organogenesis Holdings' Other Non-Current Assets stood at $1.5 million in 2022, then surged by 294.08% to $6.0 million in 2023, then dropped by 16.44% to $5.0 million in 2024, then surged by 83.88% to $9.2 million in 2025, then soared by 75.26% to $16.1 million in 2026.
- Business Quant data shows ORGO's Other Non-Current Assets at $16.1 million in Q1 2026, $9.2 million in Q4 2025, and $14.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Organogenesis Holdings | 238.69 Mn | 191.85 Mn | 20.08 Mn | 22.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.93 Mn |
| Mar 31, 2026 | 16.13 Mn |
| Dec 31, 2025 | 9.20 Mn |
| Sep 30, 2025 | 14.41 Mn |
| Jun 30, 2025 | 8.73 Mn |
| Mar 31, 2025 | 5.83 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | 5.01 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | 5.99 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.59 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 1.54 Mn |
| Sep 30, 2021 | 1.61 Mn |